Difference between revisions of "Filanesib (ARRY-520)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Drug index" to "Category:Drugs") |
|||
| Line 2: | Line 2: | ||
From the [http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=546990 NCI Drug Dictionary]: A synthetic, small molecule targeting the kinesin spindle protein (KSP) with potential antineoplastic activity. KSP inhibitor ARRY-520 specifically inhibits KSP (kinesin-5 or Eg5), resulting in activation of the spindle assembly checkpoint, induction of cell cycle arrest during the mitotic phase, and consequently cell death in tumor cells that are actively dividing. | From the [http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=546990 NCI Drug Dictionary]: A synthetic, small molecule targeting the kinesin spindle protein (KSP) with potential antineoplastic activity. KSP inhibitor ARRY-520 specifically inhibits KSP (kinesin-5 or Eg5), resulting in activation of the spindle assembly checkpoint, induction of cell cycle arrest during the mitotic phase, and consequently cell death in tumor cells that are actively dividing. | ||
| − | [[Category: | + | [[Category:Drugs]] |
[[Category:Chemotherapy]] | [[Category:Chemotherapy]] | ||
Revision as of 22:20, 13 June 2018
Mechanism of action
From the NCI Drug Dictionary: A synthetic, small molecule targeting the kinesin spindle protein (KSP) with potential antineoplastic activity. KSP inhibitor ARRY-520 specifically inhibits KSP (kinesin-5 or Eg5), resulting in activation of the spindle assembly checkpoint, induction of cell cycle arrest during the mitotic phase, and consequently cell death in tumor cells that are actively dividing.